HC Wainwright Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $361.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 10.78% from the company’s previous close.

KRYS has been the topic of several other reports. Jefferies Financial Group restated a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. The Goldman Sachs Group assumed coverage on shares of Krystal Biotech in a research note on Thursday, September 24th. They set a “buy” rating and a $441.00 target price for the company. Bank of America increased their target price on shares of Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Weiss Ratings downgraded shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, October 9th. Finally, Citigroup lifted their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Krystal Biotech currently has an average rating of “Buy” and an average price target of $377.20.

Krystal Biotech Price Performance

NASDAQ:KRYS traded up $5.61 during mid-day trading on Thursday, reaching $325.86. The stock had a trading volume of 87,721 shares, compared to its average volume of 326,221. The company has a market capitalization of $9.65 billion, a price-to-earnings ratio of 40.80 and a beta of 0.50. Krystal Biotech has a 1-year low of $183.03 and a 1-year high of $382.54. The stock’s 50 day simple moving average is $340.18 and its two-hundred day simple moving average is $324.12.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. Sell-side analysts anticipate that Krystal Biotech will post 7.40 EPS for the current fiscal year.

Insider Activity

In other news, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the sale, the director owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cornell Pochily Investment Advisors Inc. lifted its holdings in shares of Krystal Biotech by 47.7% in the third quarter. Cornell Pochily Investment Advisors Inc. now owns 3,715 shares of the company’s stock valued at $1,235,000 after buying an additional 1,200 shares during the period. IFP Advisors Inc grew its holdings in Krystal Biotech by 534.5% during the third quarter. IFP Advisors Inc now owns 349 shares of the company’s stock worth $116,000 after acquiring an additional 294 shares during the period. Terra Nova Asset Management LLC acquired a new position in Krystal Biotech during the third quarter worth about $828,000. GK Wealth Management LLC bought a new stake in Krystal Biotech in the third quarter worth about $59,000. Finally, GAMMA Investing LLC raised its position in Krystal Biotech by 10.2% in the third quarter. GAMMA Investing LLC now owns 1,100 shares of the company’s stock worth $366,000 after acquiring an additional 102 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.